CYTK · US market
Cytokinetics Inc
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$9.12bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$894.00m
- Latest-quarter run-rate earnings
- -US$795.05m
- Latest fiscal-year earnings
- -US$784.96m
- Trailing revenue
- US$67.67m
- Latest-quarter run-rate revenue
- US$114.50m
- Latest fiscal-year revenue
- US$88.04m
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- PTH · Invesco Dorsey Wright Healthcare Momentum ETF1.72% weight · Holdings dated 19 August 2026
- TMED · T. Rowe Price Health Care ETF1.69% weight · Holdings dated 30 June 2026
- BMED · iShares Health Innovation Active ETF1.61% weight · Holdings dated 21 August 2026
- FMED · Fidelity Disruptive Medicine ETF1.55% weight · Holdings dated 31 May 2026
- PXSAX · Impax Small Cap Fund Class A1.48% weight · Holdings dated 30 June 2026
- GDOC · Goldman Sachs Future Health Care Equity ETF1.40% weight · Holdings dated 31 May 2026
- SSCVX · Columbia Select Small Cap Value Fund Class A1.39% weight · Holdings dated 31 May 2026
- TCAF · T. Rowe Price Capital Appreciation Equity ETF1.34% weight · Holdings dated 30 June 2026
- WBSRX · William Blair Small Cap Growth Fund Class R61.18% weight · Holdings dated 30 June 2026
- THCRX · Thornburg Focus Growth Fund Class R31.12% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.